Literature DB >> 22566278

The direct antiglobulin test: a critical step in the evaluation of hemolysis.

Nicole D Zantek1, Scott A Koepsell, Daryl R Tharp, Claudia S Cohn.   

Abstract

The direct antiglobulin test (DAT) is a laboratory test that detects immunoglobulin and/or complement on the surface of red blood cells. The utility of the DAT is to sort hemolysis into an immune or nonimmune etiology. As with all tests, DAT results must be viewed in light of clinical and other laboratory data. This review highlights the most common clinical situations where the DAT can help classify causes of hemolysis, including autoimmune hemolytic anemia, transfusion-related hemolysis, hemolytic disease of the fetus/newborn, drug-induced hemolytic anemia, passenger lymphocyte syndrome, and DAT-negative hemolytic anemia. In addition, the pitfalls and limitations of the test are addressed. False reactions may occur with improper technique, including improper washing, centrifugation, and specimen agitation at the time of result interpretation. Patient factors, such as spontaneous red blood cell agglutination, may also contribute to false results.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22566278     DOI: 10.1002/ajh.23218

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  24 in total

1.  Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.

Authors:  Francesco Bennardello; Serelina Coluzzi; Giuseppe Curciarello; Tullia Todros; Stefania Villa
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

Review 2.  How do we diagnose immune thrombocytopenia in 2018?

Authors:  John G Kelton; John R Vrbensky; Donald M Arnold
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Methods for quantitative detection of antibody-induced complement activation on red blood cells.

Authors:  Elisabeth M Meulenbroek; Diana Wouters; Sacha Zeerleder
Journal:  J Vis Exp       Date:  2014-01-29       Impact factor: 1.355

4.  Tolerization of recent thymic emigrants is required to prevent RBC-specific autoimmunity.

Authors:  Andrea S L Wong; David R Gruber; Amanda L Richards; Kathryn Sheldon; Annie Qiu; Ariel Hay; Krystalyn E Hudson
Journal:  J Autoimmun       Date:  2020-06-03       Impact factor: 7.094

5.  Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.

Authors:  V Bhatt; L Shune; E Lauer; M Lubin; S M Devlin; A Scaradavou; R Parameswaran; M A Perales; D M Ponce; S Mantha; N A Kernan; J N Barker
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

Review 6.  [When A is not A anymore: problems and pitfalls with blood group typing].

Authors:  P Möhnle; A Humpe; G Wittmann
Journal:  Anaesthesist       Date:  2018-09       Impact factor: 1.041

Review 7.  Warm antibody autoimmune hemolytic anemia.

Authors:  Theodosia A Kalfa
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Severe hemolytic transfusion reaction due to anti-D in a D+ patient with sickle cell disease.

Authors:  Tina S Ipe; Jennifer J Wilkes; Helge D Hartung; Connie M Westhoff; Stella T Chou; David F Friedman
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

9.  Positive Direct Antiglobulin Test in COVID-19 patients: decision-making process.

Authors:  Julien Cabo; Alice Brochier; Pascale Saussoy; Marie-Astrid van Dievoet; Lena Capirchio; Bénédicte Delire; Véronique Deneys
Journal:  Transfus Clin Biol       Date:  2021-06-07       Impact factor: 1.406

10.  Ibuprofen-induced hemolytic anemia.

Authors:  Aram Barbaryan; Chioma Iyinagoro; Nwabundo Nwankwo; Alaa M Ali; Raya Saba; Shawn G Kwatra; Nasir Hussain; Chukwuemeka C Uzoka; Suartcha Prueksaritanond; Aibek E Mirrakhimov
Journal:  Case Rep Hematol       Date:  2013-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.